MetaCap

Lineage Cell Therapeutics (LCTX) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Scribe Therapeutics is the larger company by market cap ($228.6 million vs $195.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LCTX-25.06%SCTX-36.37%
+103%+30%-43%
Jul 27, 20261 yearNov 20, 2026
LCTX-28.53%SCTX-38.04%
+81%+19%-44%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LCTX versus SCTX key metrics
MetricLCTXSCTX
Share price$0.7719$12.07
Market cap$195.26M$228.58M
1-day change-5.87%-8.70%
YTD return-53.78%—
1-year return-55.64%—
5-year return-61.21%—
EPS (TTM)$-0.09$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.56M—
Revenue growth (YoY)+53.24%—
Net income (latest FY)$-63.53M—
Operating margin-251.57%—
Net margin-436.47%—
52-week high$1.99$39.60
52-week low$0.77$12.00
Distance from 52-week high-61.21%-69.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+612.53%+372.25%
Average volume1.64M403.27K
Shares outstanding252.95M18.94M
Employees7277
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lineage Cell Therapeutics

LCTX stock →

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

LCTX vs SCTX FAQ

Which is bigger, Lineage Cell Therapeutics or Scribe Therapeutics?

Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $195.26M for Lineage Cell Therapeutics (LCTX).

Are Lineage Cell Therapeutics and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons